Clinical Trials Logo

Clinical Trial Summary

In the US and Europe, bacteremia are ranked the 7th leading cause of death from all causes. E. coli is one of the main microorganism involved, responsible for 30% to 45% of bacteremia. In Europe, bacteremia E. coli, including BLSE phenotype, have a strong impact on public health, causing increased mortality, particularly in the elderly, and an increase in the average hospital stay. However, few studies have specifically concerned with the criteria associated with mortality of elderly patients with BLSE E. coli bacteremia. Finally, improving epidemiological knowledge of the elderly patients with bacteremia due to BLSE E. coli has importance in terms of public health and is a prerequisite to the development of preventive strategies and to improve the short-term prognosis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Bacteremia
  • Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor

NCT number NCT02847065
Study type Observational
Source Nantes University Hospital
Contact
Status Completed
Phase
Start date November 3, 2015
Completion date April 30, 2016